Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 8, 2013

Roche Pays PTC $10M in Spinal Muscular Atrophy Collaboration

  • PTC Therapeutics just selected a development candidate in its spinal muscular atrophy (SMA) collaboration with Roche and the SMA Foundation, triggering a $10 million payment to PTC from Roche.

    The SMA program, which PTC had initially been developing solely in partnership with the SMA Foundation, began in 2006 with the aim of identifing and optimizing compounds that increase production of the survival motor neuron (SMN) protein, the lack of which causes SMA. Then in November 2011 Roche gained an exclusive worldwide license to the SMA program, paying PTC $30 million up front and entitling PTC to $10 million based upon the selection of a development candidate. PTC may receive up to an additional $450 million upon successful completion of other development and commercialization milestones, plus royalties on net product sales worldwide.

    "We are highly encouraged by the continued progress," said Karen Chen, CSO of the SMA Foundation, in a statement. "Achieving this milestone brings us closer to developing a treatment for thousands of patients with SMA."

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »